NJ State Employees Deferred Compensation Plan cut its stake in Spark Therapeutics Inc (NASDAQ:ONCE) by 33.3% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,000 shares of the biotechnology company’s stock after selling 2,000 shares during the quarter. NJ State Employees Deferred Compensation Plan’s holdings in Spark Therapeutics were worth $410,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Sterling Investment Advisors Ltd. bought a new position in Spark Therapeutics in the 1st quarter worth $68,000. Meeder Asset Management Inc. bought a new position in shares of Spark Therapeutics in the 1st quarter worth about $121,000. Jane Street Group LLC bought a new position in shares of Spark Therapeutics in the 4th quarter worth about $378,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Spark Therapeutics by 356.7% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,207 shares of the biotechnology company’s stock worth $400,000 after acquiring an additional 7,972 shares in the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of Spark Therapeutics by 10.7% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,117 shares of the biotechnology company’s stock worth $469,000 after acquiring an additional 399 shares in the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Eighteen equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $78.45.
Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($1.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.10) by ($0.33). Spark Therapeutics had a negative net margin of 124.33% and a negative return on equity of 16.68%. The firm had revenue of $20.77 million for the quarter, compared to analysts’ expectations of $31.20 million. As a group, equities research analysts anticipate that Spark Therapeutics Inc will post -4.31 EPS for the current fiscal year.
About Spark Therapeutics
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
See Also: Liquidity
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.